4

PRIMARY DOCUMENT

Company: Apellis Pharmaceuticals, Inc.
Filed: January 4, 2022
Period of Report: January 1, 2022
Accession Number: 0001127602-22-000497

View Document ↗ View on SEC.gov ↗